Viracta Therapeutics, Inc. 4 SEC Filings

Filed On	Filing
27 Nov 2024	Form 4: Royston Ivor, Director Received 25,219 shares by exercise or conversion
27 Nov 2024	Form 4: Pomerantz Roger, Director Received 9,034 shares by exercise or conversion
12 Sep 2024	Form 4: Royston Ivor, Director Received 25,219 shares by exercise or conversion
12 Sep 2024	Form 4: Pomerantz Roger, Director Received 9,034 shares by exercise or conversion
24 Jun 2024	Form 4: Royston Ivor, Director Granted 50,000 Stock Option (Right to Buy)
24 Jun 2024	Form 4: Borellini Flavia, Director Granted 50,000 Stock Option (Right to Buy)
24 Jun 2024	Form 4: Chung Jane, Director Granted 50,000 Stock Option (Right to Buy)
24 Jun 2024	Form 4: Murphy Samuel Lafayette, Director Granted 50,000 Stock Option (Right to Buy)
24 Jun 2024	Form 4: Darcy Thomas E, Director Granted 50,000 Stock Option (Right to Buy)
24 Jun 2024	Form 4: Simon Barry J., Director Granted 50,000 Stock Option (Right to Buy)
24 Jun 2024	Form 4: Barlow Jane F, Director Granted 50,000 Stock Option (Right to Buy)
24 Jun 2024	Form 4: Pomerantz Roger, Director Granted 68,750 Stock Option (Right to Buy)
24 Jun 2024	Form 4: Rubino Stephen, Director Granted 50,000 Stock Option (Right to Buy)
29 May 2024	Form 4: Pomerantz Roger, Director Received 9,035 shares by exercise or conversion
29 May 2024	Form 4: Royston Ivor, Director Received 25,219 shares by exercise or conversion
16 May 2024	Form 4: Faerm Michael E., Chief Financial Officer Granted 500,000 Stock Option (Right to Buy)
13 Mar 2024	Form 4: Rothera Mark, Director Granted 475,000 Stock Option (Right to Buy)
13 Mar 2024	Form 4: Cohen Darrel P., Chief Medical Officer Granted 120,000 Stock Option (Right to Buy)
13 Mar 2024	Form 4: Chevallard Daniel R., CFO and COO Granted 200,000 Stock Option (Right to Buy)
27 Feb 2024	Form 4: Royston Ivor, Director Received 25,219 shares by exercise or conversion

Comments